calcimycin and Leukopenia

Platelet activating factor (PAF) production and platelet-lipoxygenase activity were studied during hemodialysis (HD) with cuprophane membranes. Six patients were treated with first-use dialyzers (FU), and 6 patients with reused dialyzers (RU). In a random and double-blind design, 2 HD were performed for each patient, with or without BN 52021 pretreatment, a selective PAF antagonist. Platelet and leukocyte counts were performed before pretreatment and 30 min before HD starting (T-30), at the beginning of HD (T0) and after 15 and 30 min of HD (T15, T30). PAF production was analyzed by direct phase HPLC. To determine platelet-lipoxygenase activity, 12-HETE was detected by reverse phase high performance liquid chromatography (HPLC) after blood stimulation by the ionophore A23187. In the FU group, PAF and 12-HETE were produced during the first 30 min of HD. After BN 52021 pretreatment, PAF production was suppressed and platelet-lipoxygenase activity reduced. In the RU group, neither PAF nor 12-HETE production occurred, and BN 52021 had no effect. We conclude that PAF, which was involved in both platelet and leukocyte activation that occurred during hemodialysis, can be considered as a bio-incompatibility marker.

Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Amyloidosis; beta 2-Microglobulin; Biocompatible Materials; Blood Platelets; Calcimycin; Cellulose; Diterpenes; Double-Blind Method; Female; Ginkgolides; Humans; Hydroxyeicosatetraenoic Acids; Lactones; Leukopenia; Lipoxygenase; Lymphocyte Activation; Male; Membranes, Artificial; Middle Aged; Platelet Activating Factor; Platelet Activation; Random Allocation; Renal Dialysis